The use of trastuzumab affected by health insurance policy in Jiangsu Province of China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The use of trastuzumab affected by health insurance policy in Jiangsu Province of China

Published:2021-01 Issue:1 Volume:10 Page:509-519
ISSN:2218-676X
Container-title:Translational Cancer Research
language:
Short-container-title:Transl Cancer Res TCR

Author:

Xia Yiqin,Zheng Mingjie,Zhan Xiang,Liu Ying,Cao Susheng,Shao Qing,Meng Dong,Jin Liyan,Xu Lingyun,Yi Tongbo,Xie Hui,Wang Shui

Publisher

AME Publishing Company

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://tcr.amegroups.com/article/download/48212/pdf

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab Accessibility and Utilization for Breast Cancer Treatment in an eastern prefecture-level city in China: Does health insurance coverage matter?;2024-07-18

2. How the National Health Insurance Coverage policy changed the use of lenvatinib for adult patients with advanced hepatocellular carcinoma: a retrospective cohort analysis with real world big data;International Journal for Equity in Health;2023-12-11

3. How National Health Insurance Coverage Policy Affected the Use of Trastuzumab and Rituximab in China: A Bicentric Retrospective Study;Risk Management and Healthcare Policy;2023-09

4. How National Health Insurance Coverage Policy Changed the Use of Lenvatinib for Adult Patients with Advanced Hepatocellular Carcinoma: A Retrospective Cohort Analysis with Real World Big Data;2023-06-26

5. Trends in anti-HER2 drugs consumption and influencing factors;Frontiers in Public Health;2022-09-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP